EGFR and cancer: It has been identified as an important drug target and understanding this gene has led to the development of multiple anti-cancer therapeutics (known as ‘EGFR inhibitors’) such as gefitinib, erlotinib, afatinib, brigatinib and icotinib for lung cancer, and cetuximab for colon cancer.